S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Palatin Technologies Stock Price, News & Analysis (NYSEAMERICAN:PTN)

$2.22
+0.22 (+11.00%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.95
$2.22
50-Day Range
$1.97
$2.91
52-Week Range
$1.43
$5.00
Volume
134,517 shs
Average Volume
62,675 shs
Market Capitalization
$30.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.00

Palatin Technologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3,053.2% Upside
$70.00 Price Target
Short Interest
Healthy
4.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars


PTN stock logo

About Palatin Technologies Stock (NYSEAMERICAN:PTN)

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

PTN Stock Price History

PTN Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Q1 2024 Palatin Technologies Inc Earnings Call
Palatin Technologies Inc. Q1 Loss decreases, but misses estimates
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Palatin Announces $5 Million Registered Direct Offering
Q4 2023 Palatin Technologies Inc Earnings Call
See More Headlines
Receive PTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/02/2023
Next Earnings (Estimated)
2/13/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:PTN
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$70.00
High Stock Price Target
$70.00
Low Stock Price Target
$70.00
Potential Upside/Downside
+3,053.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-27,540,000.00
Net Margins
-413.38%
Pretax Margin
-490.15%

Debt

Sales & Book Value

Annual Sales
$4.85 million
Book Value
($0.36) per share

Miscellaneous

Free Float
12,679,000
Market Cap
$30.50 million
Optionable
Not Optionable
Beta
0.91
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Carl Spana Ph.D. (Age 61)
    Co-Founder, President, CEO & Director
    Comp: $979k
  • Mr. Stephen T. Wills CPA (Age 66)
    MST, CFO, COO, Executive VP, Treasurer & Secretary
    Comp: $910.55k
  • Burns McClellan
    Vice President of Investor Relations
  • Mr. Stephen A. Slusher Esq.
    Chief Legal Officer
  • Dr. Michael B. Raizman M.D.
    Chief Medical Officer
  • Mr. James E. Hattersley (Age 63)
    Senior Vice President of Business Development
  • Mr. John Dodd Ph.D.
    Senior Vice President of Preclinical Development
  • Mr. Robert Jordan
    Senior Vice President of Program Operations














PTN Stock Analysis - Frequently Asked Questions

Should I buy or sell Palatin Technologies stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTN shares.
View PTN analyst ratings
or view top-rated stocks.

What is Palatin Technologies' stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Palatin Technologies' stock. Their PTN share price targets range from $70.00 to $70.00. On average, they anticipate the company's share price to reach $70.00 in the next year. This suggests a possible upside of 3,053.2% from the stock's current price.
View analysts price targets for PTN
or view top-rated stocks among Wall Street analysts.

How have PTN shares performed in 2023?

Palatin Technologies' stock was trading at $3.87 at the start of the year. Since then, PTN shares have decreased by 42.6% and is now trading at $2.22.
View the best growth stocks for 2023 here
.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 748,300 shares, an increase of 40.1% from the October 15th total of 534,300 shares. Based on an average daily volume of 116,900 shares, the days-to-cover ratio is presently 6.4 days. Currently, 5.5% of the company's shares are sold short.
View Palatin Technologies' Short Interest
.

When is Palatin Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our PTN earnings forecast
.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.07. The biopharmaceutical company had revenue of $2.11 million for the quarter, compared to analysts' expectations of $1.87 million. Palatin Technologies had a negative trailing twelve-month return on equity of 583.06% and a negative net margin of 413.38%. During the same quarter last year, the company posted ($0.86) EPS.

When did Palatin Technologies' stock split?

Palatin Technologies shares reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.24%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Palatin Technologies?

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:PTN) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -